Literature DB >> 9004284

Copper radionuclides and radiopharmaceuticals in nuclear medicine.

P J Blower1, J S Lewis, J Zweit.   

Abstract

The chemistry, radiochemistry, radiobiology, and radiopharmacology of radiopharmaceuticals containing copper radionuclides are reviewed. Copper radionuclides offer application in positron emission tomography, targeted radiotherapy, and single photon imaging. The chemistry of copper is relatively simple and well-suited to radiopharmaceutical application. Current radiopharmaceuticals include biomolecules labelled via bifunctional chelators primarily based on cyclic polyaminocarboxylates and polyamines, and pyruvaldehyde-bis(N4-methylthiosemicarbazone) (PTSM) and its analogues. The chemistry of copper, of which only a fraction has yet been exploited, is likely to be applied more fully in the future.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9004284     DOI: 10.1016/s0969-8051(96)00130-8

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  88 in total

1.  Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.

Authors:  Maggie S Cooper; Michelle T Ma; Kavitha Sunassee; Karen P Shaw; Jennifer D Williams; Rowena L Paul; Paul S Donnelly; Philip J Blower
Journal:  Bioconjug Chem       Date:  2012-04-13       Impact factor: 4.774

Review 2.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Prokineticin receptor 1 antagonist PC-10 as a biomarker for imaging inflammatory pain.

Authors:  Orit Jacobson; Ido D Weiss; Gang Niu; Gianfranco Balboni; Cenzo Congiu; Valentina Onnis; Dale O Kiesewetter; Roberta Lattanzi; Severo Salvadori; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2011-03-18       Impact factor: 10.057

4.  Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.

Authors:  Lihui Wei; Yubin Miao; Fabio Gallazzi; Thomas P Quinn; Michael J Welch; Amy L Vāvere; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

5.  Fibrin-targeted PET probes for the detection of thrombi.

Authors:  Katie L Ciesienski; Yan Yang; Ilknur Ay; Daniel B Chonde; Galen S Loving; Tyson A Rietz; Ciprian Catana; Peter Caravan
Journal:  Mol Pharm       Date:  2013-01-30       Impact factor: 4.939

6.  QSAR studies of copper azamacrocycles and thiosemicarbazones: MM3 parameter development and prediction of biological properties.

Authors:  Peter Wolohan; Jeongsoo Yoo; Michael J Welch; David E Reichert
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

7.  Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.

Authors:  Min Zhou; Yunyun Chen; Makoto Adachi; Xiaoxia Wen; Bill Erwin; Osama Mawlawi; Stephen Y Lai; Chun Li
Journal:  Biomaterials       Date:  2015-04-24       Impact factor: 12.479

Review 8.  Assessing tumor hypoxia by positron emission tomography with Cu-ATSM.

Authors:  J P Holland; J S Lewis; F Dehdashti
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-04       Impact factor: 2.346

9.  Copper and zinc bis(thiosemicarbazonato) complexes with a fluorescent tag: synthesis, radiolabelling with copper-64, cell uptake and fluorescence studies.

Authors:  SinChun Lim; Katherine A Price; Siow-Feng Chong; Brett M Paterson; Aphrodite Caragounis; Kevin J Barnham; Peter J Crouch; Josephine M Peach; Jonathan R Dilworth; Anthony R White; Paul S Donnelly
Journal:  J Biol Inorg Chem       Date:  2009-09-22       Impact factor: 3.358

Review 10.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.